Dyne Therapeutics (NASDAQ:DYN) reported quarterly losses of $(0.69) per share. This is a 38 percent decrease over losses of $(0.50) per share from the same period last year.
Galapagos’ Long-Serving CEO Onno Van De Stolpe To Exit After R&D Setbacks
After 22 years at the helm of Galapagos NV (NASDAQ:GLPG), chief executive Onno van de Stolpe has decided it is time…